New ECCO data shows subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug discontinuation
Monday 16 February 2026 07.01 | Updated: Monday 16 February 2026 07:02 Share Facebook Share on Facebook X Share on…